Skip to content
Open access

Effectiveness of Adding GLP‐1 Receptor Agonists to SGLT2 Inhibitor Therapy in Chronic Kidney Disease: A Population Based Study

Sep 2026 · Diabetes, obesity and metabolism · Vol 28, pp. 11755 - 11764 · 0 citations · 31 references
Medicine

Abstract

Individually, sodium–glucose co‐transporter‐2 inhibitors (SGLT2i) and glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs) have been shown to reduce major kidney and cardiovascular events in patients with chronic kidney disease (CKD). However, evidence supporting combined GLP‐1RA and SGLT2i therapy in this population remains limited.

Read PDF

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.